MedTrace Logo

Study of Sunobinop on Craving in Alcohol Use Disorder

NCT06545929 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-07-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol craving in subjects with moderate to severe alcohol use disorder and these subjects are seeking treatment.

Conditions

Interventions

DRUG

Sunobinop

1 tablet taken orally at bedtime

DRUG

Placebo to match sunobinop

1 tablet taken orally at bedtime

Sponsors & Collaborators

  • Purdue Pharma LP

    collaborator INDUSTRY

  • Imbrium Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-28
Primary Completion
2025-07-14
Completion
2025-07-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06545929 on ClinicalTrials.gov